Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Platt

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Carbohydrate Research|May 22, 2009
Using pulse field gradient NMR diffusion measurements to define molecular size distributions in glycan preparationsMichelle C Miller, Anatole Klyosov, David Platt, et al.
Population Health Management|August 26, 2021
Looking Upstream: Promoting Health Equity in Philadelphia through Novel Partnership StrategiesAdrea E Cope, David B Nash, Sandra E Brooks, et al.
Journal of Diabetes Science and Technology|August 31, 2014
Treatment with novel galactomannan derivative reduces 2-hour postprandial glucose excursions in individuals with type 2 diabetes treated with oral medications and/or insulinLaura E Trask, Sushela S Chaidarun, David Platt, et al.
International Journal of Molecular Sciences|July 27, 2022
PLG-007 and Its Active Component Galactomannan-α Competitively Inhibit Enzymes That Hydrolyze Glucose PolymersMichelle C Miller, Aurelio J Dregni, David Platt, et al.
Pulmonary Circulation|December 22, 2018
Riociguat improves health-related quality of life for patients with pulmonary arterial hypertension: results from the phase 4 MOTION studyNamita Sood, Alvaro Aranda, David Platt, et al.
The Biochemical Journal|May 13, 2009
The carbohydrate-binding domain on galectin-1 is more extensive for a complex glycan than for simple saccharides: implications for galectin-glycan interactions at the cell surfaceMichelle C Miller, Irina V Nesmelova, David Platt, et al.
Journal of the International Society of Sports Nutrition|February 28, 2015
The effects PCSO-524®, a patented marine oil lipid and omega-3 PUFA blend derived from the New Zealand green lipped mussel (Perna canaliculus), on indirect markers of muscle damage and inflammation after muscle damaging exercise in untrained men: a randomized, placebo controlled trialTimothy D Mickleborough, Jacob A Sinex, David Platt, et al.
Journal of Managed Care & Specialty Pharmacy|December 28, 2016
A Review of Clinical Trial Endpoints of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension and How They Relate to Patient Outcomes in the United StatesChristine Divers, David Platt, Edward Wang, et al.
Vaccines|April 28, 2023
An Oral Galectin Inhibitor in COVID-19-A Phase II Randomized Controlled TrialAlben Sigamani, Kevin H Mayo, Michelle C Miller, et al.
Carbohydrate Research|June 13, 2003
Synthesis and antitumor activity of new D-galactose-containing derivatives of doxorubicinEugenia N Olsufyeva, Anna N Tevyashova, Ivan D Trestchalin, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Carbohydrate Research|May 22, 2009
Using pulse field gradient NMR diffusion measurements to define molecular size distributions in glycan preparationsMichelle C Miller, Anatole Klyosov, David Platt, et al.
Population Health Management|August 26, 2021
Looking Upstream: Promoting Health Equity in Philadelphia through Novel Partnership StrategiesAdrea E Cope, David B Nash, Sandra E Brooks, et al.
Journal of Diabetes Science and Technology|August 31, 2014
Treatment with novel galactomannan derivative reduces 2-hour postprandial glucose excursions in individuals with type 2 diabetes treated with oral medications and/or insulinLaura E Trask, Sushela S Chaidarun, David Platt, et al.
International Journal of Molecular Sciences|July 27, 2022
PLG-007 and Its Active Component Galactomannan-α Competitively Inhibit Enzymes That Hydrolyze Glucose PolymersMichelle C Miller, Aurelio J Dregni, David Platt, et al.
Pulmonary Circulation|December 22, 2018
Riociguat improves health-related quality of life for patients with pulmonary arterial hypertension: results from the phase 4 MOTION studyNamita Sood, Alvaro Aranda, David Platt, et al.
The Biochemical Journal|May 13, 2009
The carbohydrate-binding domain on galectin-1 is more extensive for a complex glycan than for simple saccharides: implications for galectin-glycan interactions at the cell surfaceMichelle C Miller, Irina V Nesmelova, David Platt, et al.
Journal of the International Society of Sports Nutrition|February 28, 2015
The effects PCSO-524®, a patented marine oil lipid and omega-3 PUFA blend derived from the New Zealand green lipped mussel (Perna canaliculus), on indirect markers of muscle damage and inflammation after muscle damaging exercise in untrained men: a randomized, placebo controlled trialTimothy D Mickleborough, Jacob A Sinex, David Platt, et al.
Journal of Managed Care & Specialty Pharmacy|December 28, 2016
A Review of Clinical Trial Endpoints of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension and How They Relate to Patient Outcomes in the United StatesChristine Divers, David Platt, Edward Wang, et al.
Vaccines|April 28, 2023
An Oral Galectin Inhibitor in COVID-19-A Phase II Randomized Controlled TrialAlben Sigamani, Kevin H Mayo, Michelle C Miller, et al.
Carbohydrate Research|June 13, 2003
Synthesis and antitumor activity of new D-galactose-containing derivatives of doxorubicinEugenia N Olsufyeva, Anna N Tevyashova, Ivan D Trestchalin, et al.
Pageof 5